TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Benzinga Logo Benzinga By Prnewswire
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations and expanded biomarker analyses. Kazia also plans to provide the first update on its potential first-in-class PD-L1 protein degrader program.

Insights
LEN   neutral

Consistent investment by Berkshire across two share classes, no specific growth details provided


KZIA   positive

The company is well-capitalized following recent financing and has multiple near-term catalysts including anticipated clinical updates for paxalisib in triple-negative breast cancer with positive biomarker data showing CTC reductions, plus a new first-in-class PD-L1 protein degrader program update. The CEO's participation in JPM Week and strong strategic momentum indicate positive momentum.